In Mice, Psilocybin Was Linked to Less Liver Fat—at 1/50th a Trip Dose

The obese mice were supposed to get fatter. Instead, a sprinkle of psilocybin every three days turned their white-marbled livers back to healthy pink, cut weight gain by more than half, and reversed pre-diabetes—without a single psychedelic twitch.

So far, only mice. But the mechanism points to a receptor already infamous for wrecking human heart valves, which means the stakes aren’t academic. They’re surgical.

1. Skip the Trip, Hit the Liver

Psilocybin’s fame lives in the cortex, where it tickles 5-HT2A and lights up the ego. Carlo Colognesi’s team asked a quieter question: what happens if you aim for the body instead of the brain?

Serotonin receptors dot the pancreas, fat pads, and liver. Among them sits 5-HT2B, the same switch the 1990s diet drug fenfluramine hammered before it was yanked for scarring heart valves. Colognesi tried a whisper instead of a scream: 0.1 mg/kg psilocybin—roughly the amount in a fleck of dried mushroom—given every 72 hours. No hallucinations, no head-twitch, no odd behavior. Just metabolism in overdrive.

2. Twelve Weeks in Mouse Metabolism Land

Study layout was brutal in its simplicity:

• Chow + saline
• High-fat diet + saline
• High-fat diet + 0.1 mg/kg psilocybin
• High-fat diet + 0.5 mg/kg psilocybin

No calorie cuts, no running wheels. The low-dose mice still ate the same lard, yet gained only 18 % extra weight versus 42 % for controls. MRI revealed the extra mass was lean tissue, not visceral fat. Liver triglycerides dropped 40 %. Cytokines IL-6 and TNF-α nosedived. Insulin sensitivity jumped 35 %. All without the mice noticing anything unusual.

3. 5-HT2B, Not 2A, Runs the Show

Delete the 5-HT2B gene and the magic vanishes: livers re-fatten, glucose soars. A selective 5-HT2B blocker killed the benefit, but blocking 5-HT2A—the trip receptor—changed nothing. The conversation was liver-to-pancreas, not cortex-to-soul.

Downstream, the receptor flipped a PLCβ → PKC → AMPK cascade that torched fatty acids and throttled new fat synthesis. In white adipose tissue, it coaxed stubborn fat cells toward energy-burning beige. Even pancreatic β-cells sport 5-HT2B; gentle nudges there boosted glucose-dependent insulin release without runaway growth.

4. Humans: A One-Day Safety Pass

Eight healthy volunteers swallowed single micro-doses: 0.3 mg, 1 mg, 3 mg. No hallucinations, no blood-pressure drama. One volunteer felt mild nausea. Echocardiograms stayed clean. That’s day-one clearance, not a green light for months of use.

Phase 2—now recruiting—will treat metabolic-dysfunction steatotic liver disease patients for six months, tracking liver MRI fat fraction, fasting insulin, and serial cardiac imaging. The protocol halts at the first whiff of valve fibrosis or rising BNP, the heart-failure biomarker.

5. The Fen-Phen Shadow

Fenfluramine, pergolide, cabergoline—all 5-HT2B agonists that slimmed bodies until echocardiograms exposed scarred, leaky valves. The difference this time is rhythm: every third day, not daily, and only micrograms. Mice show no fibrosis after twelve weeks, but mice don’t live 40 years. Phase 2 will find, or fail to find, the narrow margin between metabolic gold and cardiac ruin.

Frequently asked questions

Q: Can I micro-dose psilocybin for my fatty liver today?
A: Don’t. Human efficacy trials haven’t started, and cardiac monitoring is non-negotiable.

Q: How is this different from psilocybin for depression?
A: Depression studies use hallucinogenic 5-HT2A doses for the mind. This uses non-hallucinogenic 5-HT2B doses for liver, fat, and pancreas—different targets, different organs.

Q: Could LSD or DMT do the same?
A: LSD hits 5-HT2B plus dozens of other receptors; DMT barely touches it. Psilocybin’s low-dose selectivity makes it the cleanest starting point.

Q: Will eating serotonin-rich foods help?
A: Dietary serotonin is gut-destroyed before it reaches the liver in useful amounts.

Q: Why chase a risky receptor at all?
A: Because nothing else reverses fatty liver and pre-diabetes simultaneously. The bet is that intermittent, low-level 5-HT2B activation can deliver metabolic gains without cardiac harm—if the dosing line holds.

Sources

Colognesi M, Gabbia D, Signor A, et al. Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms. Pharmacological Research. 2026;224:108080. https://doi.org/10.1016/j.phrs.2025.108080

Talk to a qualified clinician before making any medical decisions. This article is information, not instruction.

Educational Disclaimer

This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.